Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.

André, F; O'Regan, R; Ozguroglu, M; Toi, M; Xu, B; Jerusalem, G; Masuda, N; Wilks, S; Arena, F; Isaacs, C; Yap, Y; Papai, Z; Lang, I; Armstrong, Anne C; Lerzo, G; White, M; Shen, K; Litton, J; Chen, D; Zhang, Y; Ali, S; Taran, T; Gianni, L

Affiliation

Department of Medical Oncology, INSERM Unit U981, Université Paris Sud, Institut Gustave Roussy, Villejuif, France.

Issue Date

2014-05

Metadata

Show full item record

Abstract

Disease progression in patients with HER2-positive breast cancer receiving trastuzumab might be associated with activation of the PI3K/Akt/mTOR intracellular signalling pathway. We aimed to assess whether the addition of the mTOR inhibitor everolimus to trastuzumab might restore sensitivity to trastuzumab.

Citation

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. 2014, 15 (6):580-91 Lancet Oncol

Journal

The Lancet Oncology

URI

http://hdl.handle.net/10541/320611

DOI

10.1016/S1470-2045(14)70138-X

PubMed ID

24742739

Type

Article

Language

ISSN

1474-5488

Collections

All Christie Publications